177Lu-DOTATATE诊疗一体化:利用治疗前68Ga-DOTATATE PET和临床生物标志物预测肾脏剂量学
本研究对25例神经内分泌肿瘤患者(50个肾脏)分析治疗前68Ga-DOTATATE PET/CT摄取指标及基线临床生物标志物,构建回归模型预测177Lu-PRRT第一周期后的肾脏平均吸收剂量。单变量模型中PET摄取预测效果最佳,留一交叉验证平均绝对百分比误差为18.0%(标准差=13.3%);联合eGFR的双变量模型误差为17.3%(标准差=11.8%),较单变量模型改善甚微。作者认为治疗前肾脏PET摄取可用于预测177Lu-PRRT后SPECT导出的肾脏平均吸收剂量,平均准确度在18%以内,但需在独立队列中进一步验证后方可用于临床患者选择和个体化治疗。
要点
- 治疗前68Ga-DOTATATE PET肾脏摄取可预测177Lu-PRRT后肾脏平均吸收剂量,留一交叉验证平均绝对百分比误差18.0%(标准差=13.3%)。
- 在PET摄取基础上加入eGFR的双变量模型留一交叉验证平均绝对百分比误差17.3%(标准差=11.8%),较单变量模型改善甚微。
- 作者认为这些初步发现需在独立队列中进一步验证后,肾脏PET摄取预测方可用于临床患者选择和第一周期PRRT前的个体化治疗。
核心结论
- 治疗前68Ga-DOTATATE PET肾脏摄取可用于预测177Lu-PRRT后SPECT导出的肾脏平均吸收剂量,平均准确度在18%以内。
- 与单用PET摄取相比,在同一模型中加入eGFR以考虑患者个体动力学并未提高预测能力。
- 作者认为这些初步发现需在独立队列中进一步验证后,利用肾脏PET摄取的预测方可用于临床患者选择和第一周期PRRT前的个体化治疗。
研究设计与样本
- 研究纳入25例神经内分泌肿瘤患者(50个肾脏),分析其治疗前68Ga-DOTATATE PET/CT,并在177Lu-PRRT第一周期后约4、24、96和168小时行定量177Lu SPECT/CT显像。
- 肾脏在PET/CT和SPECT/CT的CT图像上使用经验证的深度学习工具勾画,剂量学通过将多时间点SPECT/CT图像与自建蒙特卡罗代码耦合计算。
- 以治疗前肾脏PET SUV指标、每注射活度的放射性浓度(Bq/mL/MBq)及其他基线临床因素/生物标志物为预测变量,采用单变量和双变量模型预测177Lu SPECT/CT导出的每注射活度肾脏平均吸收剂量。
- 采用留一交叉验证(LOOCV),以均方根误差和绝对百分比误差(包括平均绝对百分比误差MAPE及其标准差SD)评估模型性能。
主要发现
- 治疗交付的肾脏剂量中位数为0.5 Gy/GBq(范围0.2-1.0 Gy/GBq)。
- 单变量模型留一交叉验证中,PET摄取(Bq/mL/MBq)表现最佳,MAPE为18.0%(标准差=13.3%);eGFR的MAPE为28.5%(标准差=19.2%)。
- 联合PET摄取和eGFR的双变量回归留一交叉验证MAPE为17.3%(标准差=11.8%),较单变量模型改善甚微。
临床怎么用
- 作者认为,在这些初步发现于独立队列中进一步验证后,利用肾脏PET摄取的预测可用于临床,在启动PRRT第一周期前进行患者选择和个体化治疗。
局限性
- 作者指出这些为初步发现,需在独立队列中进一步验证后,利用肾脏PET摄取的预测方可用于临床患者选择和个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pretreatment predictions of absorbed doses can be especially valuable for patient selection and dosimetry-guided individualization of radiopharmaceutical therapy. Our goal was to build regression models using pretherapy 68Ga-DOTATATE PET uptake data and other baseline clinical factors/biomarkers to predict renal absorbed dose delivered by 177Lu-DOTATATE peptide receptor radionuclide therapy (177Lu-PRRT) for neuroendocrine tumors. We explore the combination of biomarkers and 68Ga PET uptake metrics, hypothesizing that they will improve predictive power over univariable regression. PATIENTS AND METHODS: Pretherapy 68Ga-DOTATATE PET/CTs were analyzed for 25 patients (50 kidneys) who also underwent quantitative 177Lu SPECT/CT imaging at approximately 4, 24, 96, and 168 hours after cycle 1 of 177Lu-PRRT. Kidneys were contoured on the CT of the PET/CT and SPECT/CT using validated deep learning-based tools. Dosimetry was performed by coupling the multi-time point SPECT/CT images with an in-house Monte Carlo code. Pretherapy renal PET SUV metrics, activity concentration per injected activity (Bq/mL/MBq), and other baseline clinical factors/biomarkers were investigated as predictors of the 177Lu SPECT/CT-derived mean absorbed dose per injected activity to the kidneys using univariable and bivariable models. Leave-one-out cross-validation (LOOCV) was used to estimate model performance using root mean squared error and absolute percent error in predicted renal absorbed dose including mean absolute percent error (MAPE) and associated standard deviation (SD). RESULTS: The median therapy-delivered renal dose was 0.5 Gy/GBq (range, 0.2-1.0 Gy/GBq). In LOOCV of univariable models, PET uptake (Bq/mL/MBq) performs best with MAPE of 18.0% (SD = 13.3%), and estimated glomerular filtration rate (eGFR) gives an MAPE of 28.5% (SD = 19.2%). Bivariable regression with both PET uptake and eGFR gives LOOCV MAPE of 17.3% (SD = 11.8%), indicating minimal improvement over univariable models. CONCLUSIONS: Pretherapy 68Ga-DOTATATE PET renal uptake can be used to predict post-177Lu-PRRT SPECT-derived mean absorbed dose to the kidneys with accuracy within 18%, on average. Compared with PET uptake alone, including eGFR in the same model to account for patient-specific kinetics did not improve predictive power. Following further validation of these preliminary findings in an independent cohort, predictions using renal PET uptake can be used in the clinic for patient selection and individualization of treatment before initiating the first cycle of PRRT.
引用
- Peterson AB, Wang C, Wong KK, et al. 177Lu-DOTATATE Theranostics: Predicting Renal Dosimetry From Pretherapy 68Ga-DOTATATE PET and Clinical Biomarkers. Clin Nucl Med. 2023. PMID: 37010563. doi:10.1097/RLU.0000000000004599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。